Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?

Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?

Purpose of Review With the rate of obesity increasing in the USA, effective and safe medications for weight loss are more important than ever in patient care. Glucagon-like peptide 1 receptor agonists (GLP-RA) and sodium-glucose co-transporter 2 (SGLT2) inhibitors are two medication for type 2 diabe...

Full description

Saved in:
Bibliographic Details
Published in:Current cardiovascular risk reports Vol. 17; no. 9; pp. 155 - 165
Main Authors: Watkins, Caraline, Schilling, Zoe, Kawalec, Kevin, Hulisz, Darrell
Format: Journal Article
Language:English
Published: New York Springer US 01-09-2023
Springer Nature B.V
Subjects:
Amputation
Atherosclerosis
Cardiology
Cardiovascular disease
Clinical trials
Contraindications
Diabetes
Drug dosages
Drug therapy
Ejection fraction
Family medical history
Fractures
Glucagon
Glucose
Heart failure
Hemodialysis
Insulin resistance
Kidney diseases
Medicine
Medicine & Public Health
Metabolism
Obesity
Patients
Peptides
Thrombocytopenia
Thyroid cancer
Topical Collection on Obesity and Diet
Urinary tract infections
Weight control
Type 2 diabetes
Combination therapy
GLP-RA
SGLT2I
Weight loss
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review With the rate of obesity increasing in the USA, effective and safe medications for weight loss are more important than ever in patient care. Glucagon-like peptide 1 receptor agonists (GLP-RA) and sodium-glucose co-transporter 2 (SGLT2) inhibitors are two medication for type 2 diabetes that have shown benefit in randomized control trials for not just diabetes but weight loss and lowering cardiovascular and renal risks. These novel medications have continued to show benefits in weight loss in randomized control trials. A literature review was conducted to determine the impact of GLP-RAs and SGLT2 inhibitors as combination therapy for weight loss in patients with diabetes. Another purpose of this review was to define a specific patient population that would potentially benefit from both a GLP-RA and SGLT2 for weight loss. Recent Findings Several monotherapy trials for GLP-RA and SGLT2 inhibitors have shown positive weight loss reductions along with hemoglobin A1c reductions (HbA1c) and other metabolic parameters. Several studies of combination therapy with a GLP-RA plus an SGLT2 inhibitor have shown greater weight loss than just monotherapy with either agent. Summary There are many promising studies that show significant weight loss from monotherapy and combination therapy in patients with type 2 diabetes. Further randomized control trials are needed to identify which patients would benefit most from combination therapy.
ISSN:1932-9520
1932-9563
DOI:10.1007/s12170-023-00724-3